Back to Archived Journals » Journal of Receptor, Ligand and Channel Research » Volume 8

Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential

Authors Miller M

Received 13 July 2014

Accepted for publication 9 September 2014

Published 23 December 2014 Volume 2015:8 Pages 19—30

DOI https://doi.org/10.2147/JRLCR.S50401

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Trevor W. Stone


Mindi S Miller

University of Georgia College of Pharmacy, Athens, GA, USA


Abstract: Cyclic nucleotide second messengers adenosine-3′,5′-cyclic monophosphate (cAMP) and guanosine-3′,5′-cyclic monophosphate (cGMP) influence numerous cellular functions, including inflammatory and immune responses. Intracellular levels of these nucleotides are regulated by a diverse group of phosphodiesterase enzymes. Inhibition of the various types of phosphodiesterase enzymes may offer a novel means to manage both inflammatory and autoimmune disorders. Recently, progress has been made in the development of phosphodiesterase inhibitors for a variety of conditions. This article reviews recent developments in the search for phosphodiesterase inhibitors as novel therapeutic agents for inflammatory and autoimmune conditions.

Keywords: phosphodiesterase (PDE) inhibitors, inflammatory disease, autoimmune disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]